Chemoprevention Clinical Trial of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis (APCC-19)

Abu-Helalah et al., NCT04597775, APCC-19, NCT04597775, Jan 2021

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020, now with p < 0.0000000001 from 426 studies, used in 59 countries.

No treatment is 100% effective.
Protocols combine treatments.

Estimated 93 participant HCQ prophylaxis RCT with results not reported over 5 years after estimated completion.
37 HCQ RCTs have results missing long after expected1-37
The trials report a total of 20,499 patients, with 12 trials having actual enrollment of 3,639, and the remainder estimated.
Abu-Helalah et al., 31 Jan 2021, Randomized Controlled Trial, trial NCT04597775 (history) (APCC-19). Contact: mabuhelalah@yahoo.co.uk, amer.amous@rcdcp.org.